Efficacy and safety of lopinavir/ritonavir-based antiretroviral therapy in HIV-1-infected subjects with advanced disease: a systematic review and meta-analysis. (August 2015)

• Record Type: Journal Article
• Authors: van Wyk, Jean; Fredrick, Linda M; Dorr, Pat; Madihlaba, Tshepiso
• Is Part Of: Future virology. Volume 10:Number 8(2015)
• Page Start: 949
• Page End: 959
• Publication Date: 2015-08
• Subjects: advanced HIV disease -- baseline CD4 -- baseline viral load -- lopinavir -- meta-analysis -- protease inhibitor -- ritonavir; Virology -- Periodicals; Virus diseases -- Treatment -- Periodicals; 616.9101
• DOI: 10.2217/fvl.15.66
• Languages: English
• ISSNs: 1746-0794

Abstract

ABSTRACT : Aim: We examined the literature for the efficacy, safety and tolerability of lopinavir/ritonavir (LPV/r)-based regimens in antiretroviral therapy naive HIV-1-infected subjects with advanced disease.Materials & methods: Virologic and immunologic efficacy and adverse event results from prospective, randomized controlled trials evaluating LPV/r + two nucleoside reverse transcriptase inhibitors were examined using random-effects meta-analyses. Emergence of resistance was determined using data extracted from published material.Results: Thirteen studies (including ten 96-week studies) met search criteria. Virologic responses were similar at 96 weeks between subjects with HIV-1 infection treated with LPV/r-based antiretroviral therapy when stratified by baseline HIV-1 RNA or CD4 + T-cell count; immunologic responses were similar when stratified by CD4 + T-cell count.Conclusion: Through 96 weeks of treatment, the efficacy, safety and tolerability of LPV/r-based regimens were comparable in subjects with and without advanced HIV-1 disease.